AEHR — Aehr Test Systems
Thesis
Verdict: WATCH at ~$36.76 (pre-buy checklist, 9 Mar 2026). Medium conviction — compelling pivot, unproven at scale, priced for an inflection that has not yet shown up in the financials. Aehr makes the specialized equipment that stress-tests semiconductors at the wafer level before packaging (its FOX systems plus high-margin recurring WaferPak consumables — a razor/razorblade model where each new chip design needs its own custom WaferPak). The original growth story was silicon-carbide (SiC) burn-in for EVs, which fizzled as the EV cycle disappointed. The company is now repositioning around AI processor and silicon-photonics test — a much larger, faster-growing addressable market. The catalysts signaling the pivot is real: a premier hyperscaler's initial production orders for Sonoma package-level burn-in systems, and the lead AI processor customer's $14M FOX-XP order.
The valuation has already priced most of the optimism. At ~$36.76 the market cap is ~$1.2B against ~$59M TTM revenue — ~21x EV/Revenue (TTM), while the company is unprofitable and burning cash. The stock has outrun every analyst target on the Street (consensus $21–25 vs. the $36.76 price), is up 293% from its 52-week low and 100% YTD, and trades near its $46.95 high with a beta of 2.31. The single swing factor is the $60–80M H2 FY2026 bookings guidance — it must materialize and convert into revenue over the following 2–3 quarters. Below $40M in H2 the thesis is broken; if AI orders stall and Aehr reverts to a $60–70M SiC-dependent business, fair value is ~$10–15 (where it traded mid-2025), i.e. 60–70% downside.
Return framing is asymmetric the wrong way at spot: the downside scenario is −60% to −70% to $10–15, while the stated upside target is $70+ (valuation target on ~$120M FY2027 revenue at 15x EV/Revenue). Three of the behavioral-trap checks are flagged (narrative seduction lit; FOMO and authority bias live). The discipline is to wait for at least partial bookings confirmation, or a pullback to the low $30s, before committing capital. A good pivot you may want to own, at a price that demands proof first.
Snapshot
One-liner: Aehr makes the wafer-level and package-level burn-in equipment that every AI processor, silicon-photonics device, and SiC power chip must pass before it ships — a SiC-burn-in story pivoting hard into AI/photonics test, with a real razor/razorblade WaferPak consumables franchise but extreme customer concentration and an inflection-priced multiple.
- Ticker / exchange: AEHR on NASDAQ
- Legal name: Aehr Test Systems
- Sector / industry: Semiconductors — semiconductor test / burn-in equipment (semiconductor-test)
- Spot price: ~$36.76 (checklist as of 9 Mar 2026; market cap ~$1.2B) — up 293% from the 52-wk low, +100% YTD, 52-wk high $46.95
- Valuation: EV/Revenue (TTM) ~21x | P/E N/M (unprofitable) | P/FCF N/M (FCF negative)
- Coverage / sentiment: Street consensus PT $21–25 (price trades above every target); William Blair upgraded to Outperform; beta 2.31 (extremely volatile)
- Conviction: Medium — WATCH at spot; BUY trigger on a pullback below $32 or $50M+ H2 bookings confirmation
Business
Business model. Capital-equipment sales (FOX systems) plus high-margin recurring WaferPak consumables — a razor/razorblade model in which each new chip design requires its own custom WaferPak. The consumable lock-in is the source of switching cost once a customer is ramped.
What they do. Aehr makes the equipment that stress-tests semiconductors at the wafer level before they are packaged — the quality-control gauntlet every AI chip and SiC power device passes before it ships. Aehr positions itself as the only company offering both wafer-level and package-level burn-in for AI processors and silicon photonics.
The pivot. The original growth story was silicon-carbide (SiC) burn-in for EVs, which fizzled as the EV cycle disappointed — the source of the negative 3-yr revenue CAGR. Aehr is repositioning around AI processor and silicon-photonics test, a much larger and faster-growing TAM. Two catalysts signal the pivot is real:
- A premier hyperscaler placed initial production orders for Sonoma systems (a new product platform for package-level burn-in).
- Aehr's lead AI processor customer ordered $14M in FOX-XP systems. The company is also diversifying into GaN.
Competitive position & moat. Narrow but real. Management claims no direct competitor for the FOX-XP in high-voltage wafer-level testing. The WaferPak consumable creates genuine switching costs once a customer is ramped. But the moat is thin on scale: GuruFocus rates the moat 4/10, reflecting small scale and customer concentration.
Customer concentration — RED FLAG. Top customer was 39% of FY2025 revenue; top 5 customers were 77%. In FY2023 a single customer was 79%. Diversification into AI and GaN is underway, but concentration is a material present-day risk: loss of the lead AI processor or SiC customer would be devastating.
Financials
Health snapshot (checklist, 9 Mar 2026):
| Metric | Value | Assessment |
|---|---|---|
| Revenue (TTM) | ~$59M | Trough; FY2025 down from $66M |
| Revenue growth (3-yr CAGR) | ~−5% | Negative — SiC disappointment |
| Gross margin (non-GAAP) | 29.8% (Q2 FY26) | Compressed from 45% — product-mix issue |
| Operating margin | Negative | Currently loss-making |
| Free cash flow | Negative | ($7.4M) FY2025; ($1.5M) H1 FY2026 |
| Cash | ~$31M | Boosted by $10M ATM raise |
| Debt | None | Clean balance sheet |
| ROIC | −10.6% | Negative — trough earnings |
Read-through. The business is at a revenue trough (~$59M TTM, down from ~$66M in FY2025) with a negative 3-yr CAGR. The gross-margin compression from ~45% to ~30% is the standout concern, driven by product mix. The company needs $80M+ revenue to return to meaningful profitability. Balance sheet is clean (no debt, ~$31M cash boosted by a $10M ATM raise), but it is funding the trough by burning cash and tapping the ATM.
Industry landscape
A semiconductor-test / burn-in equipment play levered to the AI-infrastructure and silicon-photonics buildout, transitioning off a disappointed SiC/EV demand base. Industry-wide detail belongs on the sector page — see semiconductor-test. Correlation note: high correlation to the semiconductor-capex cycle and AI-infrastructure spending; stacking AEHR on top of TER, AMD, or other semi-cap names concentrates that exposure.
Management
CEO Gayn Erickson has held the seat since 2012, with 35+ years in semiconductor test. Founder Rhea Posedel remains on the board. Insider ownership is 6.8% — meaningful but not exceptional. Not yet covered at deep-dive / /mgmt-dd depth; no governance red flags surfaced in the checklist beyond the customer-concentration and disclosure-scale issues noted under Business.
Catalysts & risks
Catalysts. The $60–80M H2 FY2026 bookings guidance is the gate — it must materialize and convert into revenue over the following 2–3 quarters, which would inflect FY2027 revenue sharply and compress the EV/Revenue multiple. The next earnings report is critical for bookings visibility. Sub-catalysts: Sonoma production deployment at the hyperscaler; the lead AI customer's $14M FOX-XP order converting and expanding; GaN diversification.
Risks (top 3 + structural):
- Customer concentration — top customer = 39% of revenue; loss of the lead AI processor or SiC customer would be devastating.
- Bookings miss — if H2 FY2026 bookings come in well below the $60–80M guidance, the entire re-rating unwinds. (Thesis-broken line: below $40M.)
- Execution risk on Sonoma — a new package-level burn-in platform that still must prove itself in production.
- Valuation overshoot — ~21x TTM revenue while unprofitable; price above every Street target ($21–25) → multiple compression is the most likely source of loss independent of the business.
- Margin compression — gross margin already cut from ~45% to ~30% on mix; profitability needs $80M+ revenue.
- Near-term event risk — next earnings is the binary bookings read.
Behavioral-trap audit (3 flags live):
- FOMO — stock up 293% off the 52-wk low, +100% YTD; real FOMO risk.
- Narrative seduction (lit) — the AI-pivot story is compelling, but financials are still weak: declining revenue, compressing margins, unprofitable.
- Authority bias — William Blair's upgrade to Outperform may be anchoring sentiment.
- Assessment: the narrative is ahead of the financials. Discipline requires waiting for bookings confirmation before sizing up.
What makes the thesis wrong: bookings below $40M in H2, or the hyperscaler delaying/cancelling the Sonoma deployment, or the lead AI customer cancelling/delaying.
Valuation / DCF
No DCF modeled. Multiples-based discipline only (checklist, 9 Mar 2026):
| Metric | Value |
|---|---|
| EV/Revenue (TTM) | ~21x |
| P/E | N/M (unprofitable) |
| P/FCF | N/M (FCF negative) |
Read. At ~21x TTM revenue, AEHR is priced for a massive inflection — comparable to or richer than the SiC-boom multiples of 2023. The valuation only works if FY2027 revenue reaches $100M+ with normalized 40%+ gross margins, at which point EV/Revenue compresses to ~12x. At $42+ (10–15% above spot), you pay $1.3B+ EV for ~$59M of revenue while the company loses money — thin margin of safety. A pullback to the low $30s meaningfully improves risk/reward.
Downside scenario. If AI orders stall and Aehr reverts to a $60–70M SiC-dependent business, fair value is ~$10–15 (mid-2025 levels) — 60–70% downside.
Upside / exit target. $70+ — valuation target on ~$120M FY2027 revenue at 15x EV/Revenue (also the checklist's stated sell trigger).
Decision log
2026-03-09 — Pre-buy checklist: WATCH at ~$36.76, Medium conviction. Scorecard: thesis clear ✓, business understood ✓, financials No (unprofitable, negative FCF), valuation No (~21x TTM revenue is extreme), behavioral trap Maybe (narrative seduction), technicals Mixed (uptrend but extended; a 14% drop on 6 Mar may be the start of a pullback from parabolic gains), position sized ✓ (2–3% max), exit plan ✓. The business pivot to AI is genuinely exciting but the stock has outrun every Street target (consensus $21–25 vs. $36.76); paying ~21x revenue for an unprofitable, cash-burning company. The $60–80M H2 FY2026 bookings is the swing factor — wait for at least partial confirmation before committing capital. A pullback to the low $30s or $50M+ bookings confirmation shifts the call to BUY at small size.
Single most important thing that must go right: the $60–80M H2 FY2026 bookings guidance materializes and converts into real revenue over the following 2–3 quarters.
Exit criteria: sell if H2 bookings come in below $40M (thesis broken), if the lead AI customer cancels or delays orders, or if the stock reaches $70+ (valuation target on ~$120M FY2027 revenue at 15x EV/Revenue). Expected holding period: 12–24 months.
Technical buy check (9 Mar 2026): price above 50-day and 200-day MA (golden cross — bullish); RSI(14) 59.2 (neutral, not overbought); volume normal (no distribution); beta 2.31 (extremely volatile); near 52-wk highs ($46.95) — extended. Verdict: trend up but extended; the 6 Mar −14% drop could begin a pullback; waiting for the $28–32 range (near the 50-day MA) offers a better entry.
Position plan. Conviction Medium; target size 2–3% of portfolio (speculative inflection play with binary bookings risk). Scale in: start with a 1% position on any pullback below $32; add another 1% if H2 bookings hit $50M+; full size (3%) only after bookings confirmation. Maximum loss tolerance 40% — mental stop ~$20 (below the 200-day MA), a thesis-breaking level.
Sources
Fragments folded into this canonical page (consolidated 2026-06-02; original archived to _migration-archive/2026-06-02/AEHR/): aehr-buy-checklist.md (pre-buy checklist, 9 Mar 2026).
Filings / earnings history: AEHR filings & earnings (sanctioned second file; not yet populated — run /filings AEHR).
Related vault pages: semiconductor-test
Key external references (per checklist): GuruFocus (moat 4/10); William Blair (upgrade to Outperform); company FY2025 / H1 FY2026 disclosures and management guidance ($60–80M H2 FY2026 bookings; $14M FOX-XP order; Sonoma hyperscaler order). Prices/metrics are a 9 Mar 2026 snapshot — verify live before any PT or position-sizing math.